Opendata, web and dolomites

UCRxF

A novel ulcerative colitis treatment - A phase III ready feasibility study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UCRxF project word cloud

Explore the words cloud of the UCRxF project. It provides you a very rough idea of what is the project "UCRxF" about.

clinical    immunomodulatory    drug    sequences    acute    ready    iib    companies    compounds    additional    caused    ab    portfolio    tested    debilitating    2018    license    business    milestone    active    patients    larger    cobitolimod    strategy    continue    colon    inflammation    deal    medical    cure    park    revenues    preparation    immunological    demonstrated    drugs    moderate    science    reported    mechanism    attractiveness    toxicology    sweden    commercial    ulcerative    treatment    biological    dna    efficacy    chronic    offers    reinvested    treat    dims    stockholm    asset    index    initiation    preparations    profile    fast    sales    karolinska    diseases    unmet    upfront    pharmaceuticals    company    prior    primary    safety    licensing    royalties    efficient    generate    medication    purpose    planning    broad    manufacturing    action    finance    line    institutet    uc    innovative    disease    international    pharmaceutical    q4    colitis    severe    platform    feasibility    partnering    approved    party    payments   

Project "UCRxF" data sheet

The following table provides information about the project.

Coordinator
INDEX PHARMACEUTICALS AB 

Organization address
address: TOMTEBODAVAGEN 23A
city: STOCKHOLM
postcode: 171 77
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.indexpharma.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INDEX PHARMACEUTICALS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

InDex Pharmaceuticals AB is a pharmaceutical development company based at the Karolinska Institutet Science Park in Stockholm, Sweden. The company´s primary asset is cobitolimod, which is in late phase clinical development as a new medication to treat moderate to severe active ulcerative colitis (UC); a chronic, debilitating disease with a high unmet medical need. UC is caused by chronic inflammation of the colon, and there is no cure.

Cobitolimod offers a novel and unique mechanism of action for the treatment of UC, and has demonstrated a higher efficacy and better safety profile in clinical studies than what has been reported for currently approved biological drugs. Cobitolimod is part of the broad InDex portfolio of DNA-based ImmunoModulatory Sequences (referred to as DIMS), which have the potential for treatment of various immunological diseases. Cobitolimod is currently being tested in a phase IIb clinical study with top line results expected in Q4 2018.

InDex’s business strategy is to out-license cobitolimod to a larger international pharmaceutical company prior to the initiation of clinical phase III development. This will generate revenues for InDex from upfront and milestone payments as well as royalties from third party sales, which can then be reinvested in the company to finance development of new compounds from the DIMS technology platform.

For clinical phase III, additional manufacturing and toxicology work as well as commercial preparations are essential. The planning and preparation of this work is the purpose of this feasibility study, which is a crucial part of the cobitolimod phase III ready programme, increasing the attractiveness of the asset in partnering discussions with pharmaceutical companies looking for innovative new products. A licensing deal will ensure that the development of this promising, innovative drug will continue in a fast and efficient way to reach patients with this debilitating disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCRXF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCRXF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More